Evidence map›Paper›PMID 35228584›Full record

Trial reportScientific reports2022

Probiotic normalization of systemic inflammation in siblings of type 1 diabetes patients: an open-label pilot study.

Susanne M Cabrera, Alison T Coren, Tarun Pant, Ashley E Ciecko, Shuang Jia, Mark F Roethle, Pippa M Simpson, Samantha N Atkinson, Nita H Salzman, Yi-Guang Chen and 1 more

Open access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Gut microbes
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Susanne M CabreraThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Alison T CorenThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Tarun PantThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Ashley E CieckoThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Shuang JiaThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Mark F RoethleThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Pippa M SimpsonDivision of Quantitative Health Sciences, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Samantha N AtkinsonCenter for Microbiome Research, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Nita H SalzmanCenter for Microbiome Research, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Yi-Guang ChenThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA.
Martin J HessnerThe Max McGee Research Center for Juvenile Diabetes, Children's Research Institute of Children's Wisconsin, Milwaukee, WI, USA. mhessner@mcw.edu.
Medical College of Wisconsin · USChildren’s Institute · US

Funding

Reducing innate inflammation in new onset T1D with Lactobacillus plantarumR01DK125014 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI CABRERA, SUSANNE M, HESSNER, MARTIN J · 2020 to 2024
$2.8M
Plasma-induced signatures as a measure disease heterogeneity and immunomodulation in T1D clinical trialsR01DK121528 · NIDDK · MEDICAL COLLEGE OF WISCONSIN · PI HESSNER, MARTIN J · 2020 to 2023
$1.9M
Breakthrough T1D 3-SRA-2018-478-S-BNIDDK NIH HHS R01 DK121528NIDDK NIH HHS R01DK121528NIDDK NIH HHS R01 DK125014
6 · The paper itself

Abstract

The incidence of type 1 diabetes (T1D) has increased, coinciding with lifestyle changes that have likely altered the gut microbiota. Dysbiosis, gut barrier dysfunction, and elevated systemic inflammation consistent with microbial antigen exposure, have been associated with T1D susceptibility and progression. A 6-week, single-arm, open-label pilot trial was conducted to investigate whether daily multi-strain probiotic supplementation could reduce this familial inflammation in 25 unaffected siblings of T1D patients. Probiotic supplementation was well-tolerated as reflected by high participant adherence and no adverse events. Community alpha and beta diversity were not altered between the pre- and post-supplement stool samplings. However, LEfSe analyses identified post-supplement enrichment of the family Lachnospiraceae, producers of the anti-inflammatory short chain fatty acid butyrate. Systemic inflammation was measured by plasma-induced transcription and quantified with a gene ontology-based composite inflammatory index (I.I.

Indexed as

Diabetes Mellitus, Type 1ProbioticsHumansInflammationPilot ProjectsSiblings

Identifiers

PMID35228584
PMCPMC8885673
OpenAlexW4214916676

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.